Disc Medicine Inc (NAS:IRON)
$ 34.14 -0.52 (-1.5%) Market Cap: 844.00 Mil Enterprise Value: 516.26 Mil PE Ratio: 0 PB Ratio: 2.49 GF Score: 32/100

Disc Medicine Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 13, 2023 / 12:50PM GMT
Release Date Price: $53.12 (-3.47%)
Doug Tsao
H.C. Wainwright & Co., LLC - MD, Senior Healthcare Analyst, & Moderator

Okay, good morning, everybody. Welcome, I'm Doug Tsao, Senior Analyst at H.C. Wainwright. We are happy to have with us Disc Medicine, represented by the company's CEO, John Quisel.

It's been an eventful year for the company. First, coming public through its merger with Gemini last year, and more significantly, the release of your first clinical data in patients for your lead asset, bitopertin. So maybe, John, as a starting point, just start with what bitopertin is and the condition, EPP or erythropoietic protoporphyria, the condition, what that entails, how patients are currently treated, and what we saw in the BEACON trial.

Questions & Answers

John Quisel
Disc Medicine, Inc. - CEO & President

Yeah, great. Thanks for the introduction and great to be here.

So bitopertin is a drug that we in-licensed from Roche. Roche had actually dosed in over 4,000 patients. And what it does is inhibit the uptake of glycine through a transporter called

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot